Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
J Ovarian Res ; 14(1): 5, 2021 Jan 06.
Article in English | MEDLINE | ID: mdl-33407794

ABSTRACT

BACKGROUND: Premature ovarian failure (POF) is characterized by the loss of ovarian activity before the age of 40 years. Stem cell therapy has the capability to create a regenerative microenvironment and is a proposed treatment for POF-related infertility due to the presence of renewal folliculogenesis and germ cells in the adult ovaries. In this study, we assessed the safety, feasibility, efficacy and dose adjustment of autologous adipose-derived stromal cells (ADSCs) and their ability to improve ovarian function in POF patients. METHODS: This study was a non-randomized clinical trial, phase I. Nine women with a definitive diagnosis of POF were divided into three groups (n = 3 per group) that received either 5 × 106, 10 × 106, or 15 × 106 autologous ADSCs suspension transplanted in the one ovary. Participants were followed-up at 24 h after the transplantation, and at 1 and 2 weeks, and 1, 2, 3, 6, and 12 months after the transplantation. The primary objective was to evaluate the safety of ADSCs transplantation. Secondary objectives included the effects of ADSCs transplantation on the resumption of menstruation, hormones level (Follicle-stimulating hormone (FSH) and anti-Müllerian hormone), ovarian function (Antral follicle count and ovary volume by ultrasonography evaluation) as well as dose escalation. RESULTS: Participants had not shown any early-onset possible side effects and secondary complications during follow-up. The menstruation resumption was observed in four patients which established for several months. In the 15 × 106 group, two POF patients had a return of menstruation second months after the intervention. Two other POF patients in 5 × 106 and 10 × 106 cell groups reported menstruation resumption at 1 month after the intervention. We observed decreased serum FSH levels of less than 25 IU/l in four patients. In two patients in 5 × 106 and 10 × 106 cell groups, serum FSH showed an inconsistent decline during a 1 year follow up after ADSCs transplantation. The ovarian volume, AMH, and AFC were variable during the follow-up and no significant differences between cell groups (p > 0.05). CONCLUSIONS: We showed the intra-ovarian embedding of ADSCs is safe and feasible and is associated with an inconsistent decline in serum FSH. This should be further investigated with a large RCT. TRIAL REGISTRATION: NCT02603744 , Registered 13 November 2015 - Retrospectively registered, http://www.Clinicaltrials.gov.


Subject(s)
Mesenchymal Stem Cells/metabolism , Ovarian Reserve/drug effects , Primary Ovarian Insufficiency/therapy , Stem Cell Transplantation/methods , Adult , Feasibility Studies , Female , Humans , Primary Ovarian Insufficiency/pathology , Young Adult
2.
J Photochem Photobiol B ; 151: 180-5, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26298068

ABSTRACT

OBJECTIVE: This study evaluated the effect of Low Level Laser Therapy (LLLT) and Mesenchymal Stem Cells (MSCs) on bone regeneration. BACKGROUND DATA: Although several studies evaluated the effects of MSCs and LLLT, there is little information available regarding in vivo application of LLLT in conjunction with MSCs. METHODS: Forty-eight circular bone defects (6mm in diameter) were prepared in the calvaria of 12 New-Zealand white rabbits. The defects of each animal were randomly assigned to 4 groups: (C) no treatment; (L) applying LLLT; (SC) filled with MSCs; (SCL) application of both MSCs and LLLT. LLL was applied on alternate days at wavelength of 810 nm, power density of 0.2 W/cm(2) and a fluency of 4 J/cm(2) using a Gallium-Aluminum-Arsenide (GaAlAs) diode laser. The animals were sacrificed after 3 weeks and then histological samples were evaluated to determine the amount of new bone formation and the remaining scaffold and inflammation. RESULTS: The histological evaluation showed a statistically significant increase in new bone formation of LLLT group relative to the control and the other two experimental groups (p<0.05). There was no significant difference in bone formation of the control group compared to experimental groups filled with MSCs. Laser irradiation had no significant effect on resorption of the scaffold material. In addition, inflammation was significantly reduced in LLLT group compared to the control defects and the other two experimental groups. CONCLUSION: Low level laser therapy could be effective in bone regeneration but there is no evidence of a synergistic effect when applied in conjunction with MSCs.


Subject(s)
Bone Regeneration/radiation effects , Low-Level Light Therapy/methods , Mesenchymal Stem Cell Transplantation/methods , Skull , Animals , Autografts , Bone Regeneration/physiology , Male , Mesenchymal Stem Cells/cytology , Mesenchymal Stem Cells/physiology , Rabbits , Skull/injuries , Skull/surgery , Tissue Scaffolds
3.
Sci Rep ; 5: 9322, 2015 Mar 30.
Article in English | MEDLINE | ID: mdl-25818803

ABSTRACT

Islet transplantation has been hampered by loss of function due to poor revascularization. We hypothesize that co-transplantation of islets with human embryonic stem cell-derived mesenchymal stromal cells that conditionally overexpress VEGF (hESC-MSC:VEGF) may augment islet revascularization and reduce the minimal islet mass required to reverse diabetes in mice. HESC-MSCs were transduced by recombinant lentiviruses that allowed conditional (Dox-regulated) overexpression of VEGF. HESC-MSC: VEGF were characterized by tube formation assay. After co-transplantation of hESC-MSC:VEGF with murine islets in collagen-fibrin hydrogel in the omental pouch of diabetic nude mice, we measured blood glucose, body weight, glucose tolerance and serum C-peptide. As control, islets were transplanted alone or with non-transduced hESC-MSCs. Next, we compared functional parameters of 400 islets alone versus 200 islets co-transplanted with hESC-MSC:VEGF. As control, 200 islets were transplanted alone. Metabolic function of islets transplanted with hESC-MSC:VEGF significantly improved, accompanied by superior graft revascularization, compared with control groups. Transplantation of 200 islets with hESC-MSC:VEGF showed superior function over 400 islets alone. We conclude that co-transplantation of islets with VEGF-expressing hESC-MSCs allowed for at least a 50% reduction in minimal islet mass required to reverse diabetes in mice. This approach may contribute to alleviate the need for multiple donor organs per patient.


Subject(s)
Diabetes Mellitus/therapy , Human Embryonic Stem Cells/transplantation , Islets of Langerhans Transplantation , Mesenchymal Stem Cell Transplantation , Vascular Endothelial Growth Factor A/genetics , Animals , Diabetes Mellitus/metabolism , Diabetes Mellitus/pathology , Gene Expression , Humans , Islets of Langerhans/pathology , Mesenchymal Stem Cells/cytology , Mesenchymal Stem Cells/metabolism , Mice , Vascular Endothelial Growth Factor A/biosynthesis
4.
Int J Organ Transplant Med ; 1(4): 157-69, 2010.
Article in English | MEDLINE | ID: mdl-25013581

ABSTRACT

Progress in understanding the cellular and molecular biology of the immune system, in the second half of the 20(th) century brings the transplantation of replacement organs and tissues in clinical reality to cure disease. Immunosuppressive agents that are part of nearly every transplantation procedure, are toxic to some extent and their chronic use predisposes the patient to the development of infection and cancer. Alternatives to immunosuppression include modulation of host immune system to reduce the immune response and the induction of a state of immunologic tolerance. Induction of hematopoietic mixed chimerism through donor bone marrow transplantation offers a promising approach for tolerance induction as a prelude to organ transplantation. Furthermore, mesenchymal stromal cells have important effects on the host immune system and possess immune modulation properties that make them attractive for potential use in organ transplantation as immunosuppressant. Both modalities might potentially provide novel therapeutic options for treatment/prevention of rejection and/or repair of organ allografts through their multifaceted properties. In this review, evidences for the tolerogenic properties and mechanisms of hematopoietic mixed chimerism as well as mesenchymal stromal cells effects on allograft surveillance are summarized.

5.
Bone Marrow Transplant ; 42(12): 807-18, 2008 Dec.
Article in English | MEDLINE | ID: mdl-18820712

ABSTRACT

GVHD is a major complication in allogeneic SCT. Available GVHD models are mainly based on radiotherapy-conditioning and/or immune deficient mice. GVHD models based on chemotherapy-based regimens remain poorly studied, despite 50% of all transplantations being chemotherapy based. Our aim was to develop a GVHD model using chemotherapy as conditioning. Female BALB/c (H-2Kd) were conditioned with BU-CY and transplanted with 2 x 10(7) BM and 3 x 10(7) spleen cells from either C57BL/6 (H-2 Kb) mice (allogeneic setting) or from male BALB/c to serve as a control group for regimen-related toxicity and engraftment. GVHD manifestations and histopathological changes were evaluated. Chimerism and donor T cells presence in skin, intestine and liver were studied using FACS-, FISH analysis and immunohistochemistry. Allogeneic transplanted mice developed lethal GVHD starting from day+7 with both histological and clinical signs. Donor T cells accumulated in recipient skin and intestine with GVHD progression. BM-failure, apoptosis and T-lymphocyte infiltration into target organs were significantly higher in allogeneic when compared with the syngeneic group. No toxicity or GVHD signs were observed in the syngeneic setting. We report a mouse model of GVHD using BU-CY conditioning that represents the most common myeloablative-conditioning regimen in clinical SCT. This model can be utilized to study the role of conditioning on mechanisms underlying GVHD.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Graft vs Host Disease/etiology , Hematopoietic Stem Cell Transplantation/adverse effects , Transplantation Conditioning/adverse effects , Transplantation Conditioning/methods , Animals , Antineoplastic Agents, Alkylating/administration & dosage , Busulfan/administration & dosage , Cyclophosphamide/administration & dosage , Disease Models, Animal , Dose-Response Relationship, Drug , Female , Graft vs Host Disease/physiopathology , Male , Mice , Transplantation, Homologous/adverse effects
6.
Ann Oncol ; 17(1): 131-4, 2006 Jan.
Article in English | MEDLINE | ID: mdl-16227315

ABSTRACT

INTRODUCTION: Arsenic trioxide is effective and approved for treatment of relapsed or refractory acute promyelocytic leukemia (APL) cases resistant to all-trans retinoic acid (ATRA), but its effect on new cases of APL is not clear. MATERIALS AND METHODS: We studied 111 patients with APL. Arsenic trioxide was infused at 0.15 mg/kg daily dose, until complete remission was achieved. Then, after 28 days of rest, arsenic trioxide was infused daily for 28 days as consolidation therapy. We studied minimal residual disease (MRD) by semi-sensitive reverse transcription polymerase chain reaction (RT-PCR) on peripheral blood samples. RESULTS: Complete remission was observed in 95 patients (85.6%). With the median (range) follow-up period of 16.5 (1-57) months, 1- and 2-year disease-free survival was 88.3% and 63.7%, respectively; 24 patients relapsed, 19 of whom achieved a second complete remission, again by arsenic trioxide. Third and fourth remissions were seen in some relapsed patients, again by arsenic trioxide. For patients in complete remission, 1- and 3-year survival was 95.5% and 87.6%, respectively. MRD was positive in four (8.3%) out of 48 cases during 1 year after remission induction; three of them relapsed clinically. CONCLUSIONS: Arsenic trioxide is effective as first-line treatment for APL. Results of arsenic trioxide combination therapy with chemotherapy/ATRA requires further study.


Subject(s)
Antineoplastic Agents/therapeutic use , Arsenicals/therapeutic use , Leukemia, Promyelocytic, Acute/drug therapy , Oxides/therapeutic use , Adolescent , Adult , Aged , Arsenic Trioxide , Child , Disease-Free Survival , Female , Humans , Leukocytosis , Male , Middle Aged , Neoplasm Proteins/genetics , Neoplasm Proteins/metabolism , Neoplasm Recurrence, Local/drug therapy , Neoplasm, Residual/drug therapy , Oncogene Proteins, Fusion/genetics , Oncogene Proteins, Fusion/metabolism , Prognosis , Remission Induction , Reverse Transcriptase Polymerase Chain Reaction , Survival Rate , Treatment Outcome
7.
East Mediterr Health J ; 10(6): 921-4, 2004 Nov.
Article in English | MEDLINE | ID: mdl-16335780

ABSTRACT

We carried out a case-control study is to investigate the relationship between iodine deficiency and stomach cancer. We compared the ratio of urinary iodine to urinary creatinine in 100 patients diagnosed with stomach cancer and 84 people in a control group. Mean urinary iodine levels were lower in the patients with stomach cancer, 61.9 microg/g creatinine, compared to 101.7 microg/g creatinine in the control group (P < 0.0001). More of the cancer patients (49.0%) had severe iodine deficiency (< 25 microg/g creatinine) than people in the control group (19.1%) (P< 0.0001). We found the relationship between stomach cancer and iodine deficiency to be significant.


Subject(s)
Creatinine/urine , Iodine , Malnutrition , Stomach Neoplasms/etiology , Stomach Neoplasms/urine , Adolescent , Adult , Aged , Aged, 80 and over , Case-Control Studies , Feeding Behavior , Female , Food, Fortified , Gastritis, Atrophic/complications , Humans , Intestinal Absorption , Iodine/deficiency , Iodine/urine , Iran/epidemiology , Male , Malnutrition/complications , Malnutrition/urine , Middle Aged , Risk Factors , Severity of Illness Index , Sodium Chloride, Dietary , Stomach Neoplasms/epidemiology
8.
(East. Mediterr. health j).
in English | WHO IRIS | ID: who-116910

ABSTRACT

We carried out a case-control study is to investigate the relationship between iodine deficiency and stomach cancer. We compared the ratio of urinary iodine to urinary creatinine in 100 patients diagnosed with stomach cancer and 84 people in a control group. Mean urinary iodine levels were lower in the patients with stomach cancer, 61.9 micro g/g creatinine, compared to 101.7 micro g/g creatinine in the control group [P < 0.0001]. More of the cancer patients [49.0%] had severe iodine deficiency [< 25 micro g/g creatinine] than people in the control group [19.1%] [P< 0.0001]. We found the relationship between stomach cancer and iodine deficiency to be significant


Subject(s)
Creatinine , Iodine , Stomach Neoplasms , Iran
SELECTION OF CITATIONS
SEARCH DETAIL
...